
Conference Coverage
Latest Content

Clinical Data From Phase 3 ADEPT Studies Evaluating KarXT for Alzheimer Disease Psychosis

Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 Years

Podcast: NIH Team Details Path From Ketamine Metabolite Discovery to Phase 2 Trials

sNDA Submitted: Caplyta for the Treatment of Bipolar Mania

Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic

Shorts










Digital Edition
Continuing Medical Education
All News

Learn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more.

In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.

New phase 3 data for a PDE-5 inhibitor in Alzheimer disease.

Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.

Review news from the last week in pharmacology, legislation, and research.

Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.

The FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use.

A critical care physician explains why quiet, hypoactive ICU delirium is often missed and why its effects follow patients long after discharge.

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
















































